Meeting
2011 ASCO Annual Meeting
Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12.
Authors
M. Gnant
Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
M. Gnant , B. Mlineritsch , H. Stoeger , G. Luschin-Ebengreuth , S. Poestlberger , P. C. Dubsky , R. Jakesz , C. F. Singer , H. Eidtmann , R. Greil
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 29: 2011 (suppl; abstr 520)
Abstract #
520
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.
First Author: Georg Pfeiler
Poster
2014 ASCO Annual Meeting
Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial.
First Author: Georg Pfeiler
Poster
2011 ASCO Annual Meeting
Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.
First Author: G. Pfeiler
Poster
2017 ASCO Annual Meeting
Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
First Author: Vivianne C. Tjan-Heijnen